C. Overshiner - Concepedia

Author

C. Overshiner

Eli Lilly (United States)

Also Known As

C D Overshiner, C. Overshiner, C.D. Overshiner, Carl D. Overshiner, Carl Overshiner

Publications

638

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Eli Lilly (United Kingdom)

About

C. Overshiner is an author at Eli Lilly (United States) specializing in social sciences, pharmacotherapy, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	141
2	Social Sciences	3	3	135
3	Biochemistry	1	1	18
4	Cognitive Science	1	1	12
5	Endocrinology	1	1	18

C. Overshiner

Publications

596

Citations

H-Index

Page 1

	Year	Citations
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine Eleni T. Tzavara, Frank P. Bymaster, C. Overshiner, Molecular Psychiatry NeurophysiologyMedicinePhysiologyPsychopharmacologyNeuropharmacology	2005	107
The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits J M Witkin, James A. Monn, Darryle D. Schoepp, Journal of Pharmacology and Experimental Therapeutics	2016	104
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes Matthew Fell, Jeffrey M. Witkin, Julie F. Falcone, Journal of Pharmacology and Experimental Therapeutics	2010	99
M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine Jeffrey M. Witkin, C. Overshiner, X. Li, Journal of Pharmacology and Experimental Therapeutics	2014	95
The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine Kurt Rasmussen, David O. Calligaro, Janet F. Czachura, Journal of Pharmacology and Experimental Therapeutics	2000	58
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression. Jeffrey M. Witkin, S.N. Mitchell, Keith A. Wafford, Journal of Pharmacology and Experimental Therapeutics	2017	42
In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder V. Barth, Anne B. Need, Eleni T. Tzavara, Journal of Pharmacology and Experimental Therapeutics	2012	32
Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist Mary C. Wolff, Mark J. Benvenga, David O. Calligaro, Drug Development Research PharmacotherapyExperimental PharmacologyMolecular PharmacologyNeurochemistryBiochemistry	1997	18
Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons Mark J. Benvenga, C. Overshiner, James A. Monn, Drug Development Research Disinhibitory EffectsPsychopharmacologyPharmacotherapyExperimental PharmacologySocial Sciences	1999	16
Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder Michelle M. Rodriguez, C. Overshiner, J. David Leander, Frontiers in Psychiatry	2017	13

Page 1